Digestive Tract Cancer-Related Adverse Events Correlated with Proton Pump Inhibitors Use: A Pharmacovigilance Study of the FDA Adverse Event Reporting System

<div>Signal strength of different PPIs correlated with BDNM at the PTs level. (a) Forest plot of signal detections for different PPIs and BDNM. (b) Forest plot of signal detections for PPIs as a whole and PTs subordinated to the HLT “BDNM” after removing parts of PTs for the low number of reported cases. (c) Heatmap of signal strength for different PPIs correlated with PTs subordinated to the HLT “BDNM” (ROR lower bound of 95% CI). PPIs, proton pump inhibitors; BDNM, bile duct neoplasms malignant; PTs, preferred terms; HLT, high-level term; ROR, reporting odds ratio; CI, confidence interval.</div>

Journal of Clinical Pharmacy and Therapeutics

fig5

Figure 5

Figure 5: Digestive Tract Cancer-Related Adverse Events Correlated with Proton Pump Inhibitors Use: A Pharmacovigilance Study of the FDA Adverse Event Reporting System 

Figure 5 | Digestive Tract Cancer-Related Adverse Events Correlated with Proton Pump Inhibitors Use: A Pharmacovigilance Study of the FDA Adverse Event Reporting System 